This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Benzinga · 09/22 12:43
Share
Listen to the news
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Barclays analyst Eddie Kim upgraded Helmerich & Payne, Inc. (NYSE:HP) from Equal-Weight to Overweight and raised the price target from $17 to $25. Helmerich & Payne shares closed at $20.54 on Friday. See how other analysts view this stock.
- UBS analyst Alex Kramm upgraded the rating for FactSet Research Systems Inc. (NYSE:FDS) from Neutral to Buy but lowered the price target from $480 to $425. FactSet Research shares closed at $289.15 on Friday. See how other analysts view this stock.
- BMO Capital analyst Kostas Biliouris upgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT) from Market Perform to Outperform and maintained the price target of $50. Sarepta Therapeutics shares closed at $17.43 on Friday. See how other analysts view this stock.
- Evercore ISI Group analyst Daniel Markowitz upgraded Repligen Corporation (NASDAQ:RGEN) from In-Line to Outperform and raised the price target from $130 to $155. Repligen shares closed at $122.30 on Friday. See how other analysts view this stock.
- Wells Fargo analyst Zachary Fadem upgraded the rating for Brinker International, Inc. (NYSE:EAT) from Equal-Weight to Overweight and boosted the price target from $165 to $175. Brinker International shares closed at $136.35 on Friday. See how other analysts view this stock.
Considering buying SRPT stock? Here’s what analysts think:
Read This Next:
Photo via Shutterstock
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2025 Webull. All Rights Reserved